Skip to Main Content
Back to News

Insider Sale: President & CEO of $CRNX Sells 4,000 Shares

Automated

Richard Scott Struthers, the President & CEO of $CRNX, sold 4,000 shares of the company on 09-26-2025 for an estimated $180,000. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.6% of their shares of this class of stock. Following this trade, they now own 106,000 shares of this class of $CRNX stock.

$CRNX Insider Trading Activity

CRNX Insider Trades

$CRNX insiders have traded $CRNX stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.

Here’s a breakdown of recent trading of $CRNX stock by insiders over the last 6 months:

  • STEPHEN F. BETZ (Chief Scientific Officer) sold 97,483 shares for an estimated $3,141,877
  • DANA PIZZUTI (Chief Med and Dev Officer) has made 0 purchases and 3 sales selling 41,492 shares for an estimated $1,262,836.
  • MATTHEW K FUST sold 16,000 shares for an estimated $716,000
  • RICHARD SCOTT STRUTHERS (President & CEO) sold 4,000 shares for an estimated $180,000

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$CRNX Hedge Fund Activity

We have seen 127 institutional investors add shares of $CRNX stock to their portfolio, and 101 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$CRNX Congressional Stock Trading

Members of Congress have traded $CRNX stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $CRNX stock by members of Congress over the last 6 months:

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$CRNX Analyst Ratings

Wall Street analysts have issued reports on $CRNX in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • Oppenheimer issued a "Outperform" rating on 09/30/2025
  • Leerink Partners issued a "Outperform" rating on 09/29/2025
  • Baird issued a "Outperform" rating on 09/26/2025
  • JMP Securities issued a "Market Outperform" rating on 09/26/2025
  • JP Morgan issued a "Overweight" rating on 09/24/2025
  • HC Wainwright & Co. issued a "Buy" rating on 06/27/2025

To track analyst ratings and price targets for $CRNX, check out Quiver Quantitative's $CRNX forecast page.

$CRNX Price Targets

Multiple analysts have issued price targets for $CRNX recently. We have seen 8 analysts offer price targets for $CRNX in the last 6 months, with a median target of $79.0.

Here are some recent targets:

  • Leland Gershell from Oppenheimer set a target price of $87.0 on 09/30/2025
  • Joseph Schwartz from Leerink Partners set a target price of $88.0 on 09/29/2025
  • Jeffrey Hung from Morgan Stanley set a target price of $77.0 on 09/29/2025
  • Jonathan Wolleben from JMP Securities set a target price of $143.0 on 09/26/2025
  • Brian Skorney from Baird set a target price of $62.0 on 09/26/2025
  • Richard Law from Goldman Sachs set a target price of $40.0 on 09/26/2025
  • Jessica Fye from JP Morgan set a target price of $52.0 on 09/24/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles